On Apr. 30, 2020, InBios announced that it had been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, to develop the SCoV-2 Detect IgM/IgG Rapid Test, a point-of-care test for detection of SCoV-2 specific IgM/IgG antibodies.

The lateral flow serodiagnostic test used blood products, from finger-prick samples, to identify people infected with severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. This point-of-care assay detected SARS-CoV-2 reactive antibodies as host biomarkers.